Clinical trials · Houston, TX
B Cell Malignancies clinical trials in Houston
We’re tracking 68 recruiting b cell malignancies studies with a site in or near Houston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Houston
- NCT06137144RecruitingPhase 1/Phase 2
AZD3470 for lymphoma that has come back or not responded
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
Houston, TexasAges 12 years+ - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Houston, TexasAges 18 years+ - NCT07283679RecruitingPhase 1/Phase 2
NK cell therapy with two immune agents for returning lymphoma
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Houston, TexasAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Houston, TexasAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Houston, TexasAges 6 months–25 years - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Houston, TexasAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Houston, TexasAges 18 years+ - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Houston, TexasAges 18 years+ - NCT06792734RecruitingPhase 1
Testing BTM-3566 for lymphoma that has returned
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT03114462RecruitingPhase 1
Study of focused radiation for laryngeal cancer
This Phase 1 study tests a precise type of radiation treatment for people with certain stages of laryngeal (voice box) squamous cell cancer. The goal is to see how safe the treatment is and how well it may work in shrinking or controlling the cancer while aiming to preserve the larynx.
Houston, TexasAges 18 years+ - NCT07444632RecruitingPhase 1
Gene-modified cord blood cells for advanced blood cancers
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
Houston, TexasAges 18–75 - NCT06807606RecruitingPhase 2
Cord blood transplant after relapse from first transplant
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Houston, TexasAges Up to 60 years - NCT06930651RecruitingPhase 1/Phase 2
Engineered NK cell therapy for relapsed blood cancers
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
Houston, TexasAges 18–80 - NCT05010564RecruitingPhase 1
TRICAR-ALL CAR-T treatment for tough childhood leukemia
This Phase 1 trial tests a customized CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that keeps coming back or doesn’t respond to treatment. It aims to find a safer and effective way to control leukemia by targeting specific markers on the leukemia cells.
Houston, TexasAges 1–25 - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Houston, TexasAges 18 years+ - NCT06045247RecruitingPhase 2
Epcoritamab with gentler chemo for older adults with lymphoma
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
Houston, TexasAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Houston, TexasAges 18 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Houston, TexasAges 18 years+ - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Houston, TexasAges 12 years+
Hear when a new B Cell Malignancies trial opens near Houston, TX
We’ll email you when one opens near Houston, TX — at most once a week, no account needed, unsubscribe anytime.
B Cell Malignancies trials in other cities
Where these studies are running near Houston
Institutions with a site for the recruiting b cell malignancies studies listed above.
- The University of Texas MD Anderson Cancer Center · 18 studies
- Research Site · 2 studies
- Texas Children's Hospital · 2 studies
- Baylor College of Medicine
- Ben Taub General Hospital
- Center for Oncology and Blood Disorders
- Oncology Consultants
What taking part in a b cell malignancies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting b cell malignancies studies in Texas.
Common questions
- Are there b cell malignancies clinical trials near Houston?
- Yes. We're currently tracking 68 recruiting b cell malignancies studies with a site near Houston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a b cell malignancies study near Houston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Houston to take part?
- Not necessarily. These studies have a site near Houston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New b cell malignancies studies open near Houston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.